Table 1.
Baseline characteristics of COVID-19 patients who presented with silent hypoxia (n=8).
| All patients (n = 8) | |
|---|---|
| Age, years | 61.00 (48.75–72.25) |
| Male | 5 (62.50) |
| Body mass index, kg/m2 | 22.69 (18.15–25.99) |
| Smoking | 2 (25.00) |
| Days from onset to admission | 6 (4.50–6.25) |
| Comorbidities | |
| Hypertension | 4 (50.00) |
| Diabetes | 1 (12.50) |
| Respiratory disorders | 1 (12.50) |
| Symptoms | |
| Fever | 8 (100) |
| Cough | 3 (37.50) |
| Short breath | 0 (0.00) |
| Dysosmia | 0a (0.00) |
| Laboratory data | |
| White blood cell, ×103/μL | 5.04 (3.65–6.88) |
| Lymphocyte, % | 14.55 (13.43–21.57) |
| AST, U/L | 36.50 (33.75–80.00) |
| ALT, U/L | 37.00 (24.25–70.50) |
| LDH, IU/L | 328 (318–430) |
| CRP, mg/dL | 5.53 (4.57–7.53) |
| D-Dimer, ng/mL | 1500 (800–3800) |
| CT findings | |
| Days from onset to receiving CT | 6 (4.5–7.5) |
| COVID-19 CT score | 13.50 (10.75–15.25) |
| Ground Grass Opacities | 8 (100) |
| Consolidation | 6 (75.00) |
| Pulmonary emphysema | 1 (12.50) |
| Pulmonary fibrosis | 3 (37.50) |
| Plural effusion | 3 (37.50) |
| Fatty liver | 5 (50.00) |
Unless otherwise stated, data are presented as n (%).
Continuous variable data are presented as median (interquartile range).COVID-19; coronavirus disease 2019, AST; aspartate aminotransferase, ALT; alanine aminotransferase, LDH; lactate dehydrogenase, CRP; C-reactive protein, CT; computerized tomography.
a
One patient lacked information on the presence of dysosmia.